Redoxis AB is a research focused CRO with long experience of preclinical efficacy models of autoimmunity. Preclinical models of autoimmune inflammatory diseases resemble complex human diseases and are affected by both genetic and environmental factors. Different models represent different phases and characteristics of the human diseases. Therefore, the most critical aspects of preclinical drug efficacy studies are the choice of a proper model and study design.
Redoxis main expertise and knowledge is within the area of rheumatoid arthritis (RA), multiple sclerosis (MS) and chronic inflammation. We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo. In addition to efficacy studies of treatment in vivo, we offer analytical services of immunological characterisation and bioavailability analyses. Redoxis senior scientists have many years of experience in the area of drug development and inflammatory experimental models with a deep understanding of the immunological processes underlying autoimmune diseases. Our goal is to provide high cost value studies and efficient service delivery.
Preclinical efficacy studies of autoimmune diseases
Redoxis have a strong portfolio of arthritis models including the most commonly used models Collagen induced arthritis (CIA) and collagen antibody induced arthritis (CAIA). Redoxis also provide models of arthritis in rats including CIA and the more T cell specific models of arthritis pristane induced arthritis (PIA) and adjuvant induced arthritis (AIA).
Redoxis provides models of inflammatory induced EAE (Experimental Autoimmune Encephalomyelitis, models for MS) in both rats and mice, induced with proteins or peptides derived from the CNS.
Redoxis also provides ex vivo systems for early drug validation. These models are based on analysis of the test compound directly on autoreactive primary cells and are useful for early drug characterization and lead compound selection.
We tailor-make studies for preclinical drug validation in models of Arthritis and MS. In addition, Redoxis develop and optimise more specific preclinical efficacy models of chronic inflammation. Please find a more detailed description of the models we provide at our updated homepage (www.redoxis.com).